TransCode Therapeutics

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of an aggregate of 16,863,000 shares of its common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof), including the partial exercise of the underwriter's over-allotment option. Each share of common stock (or Pre-Funded Warrant) was sold at a public offering price of $0.51 per share (inclusive of the Pre-Funded Warrant exercise price of $0.01 per share). All of the shares and Pre-Funded Warrants in the offering were sold by the Company. Total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $8.5 million. The Company has granted the underwriters a 45-day option to purchase up to 2,339,200 additional shares of its common stock and/or Pre-Funded Warrants at the public offering price less the underwriting discount, which the underwriter has partially exercised to purchase 1,163,000 Pre-Funded Warrants at the closing.

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

TransCode Therapeutics (NASDAQ: RNAZ ) stock is falling hard on Tuesday after the medical company announced a public share offering. According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each.

Why Is TransCode Therapeutics (RNAZ) Stock Down 69% Today?

TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monday, before coming back down to earth with an after-hours equity raise. On the back of preclinical results the RNA oncology stock traded as high as $3.20 and closed at $2.55, from a starting price of 66 cents.

Transcode Therapeutic stock whipsaws lower after cut price placing

BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its underwritten public offering of an aggregate of 15,700,000 shares of its common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being sold at a public offering price of $0.51 per share (inclusive of the Pre-Funded Warrant exercise price of $0.01). All of the shares and Pre-Funded Warrants in the offering are being sold by the Company. Total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $8 million. In addition, the Company has granted the underwriters a 45-day option to purchase up to 2,339,200 additional shares of its common stock and/or Pre-Funded Warrants at the public offering price less the underwriting discount.

TransCode Therapeutics Announces Pricing of $8 Million Public Offering

Enlivening a soft Monday session on Wall Street, TransCode Therapeutics (NASDAQ: RNAZ ) saw its shares drive up 300% earlier this morning before settling around 240% up in the early afternoon session. Catapulting sentiment was news that TransCode's lead therapeutic candidate, TTX-MC138, demonstrated encouraging pre-clinical results.

Why Is TransCode Therapeutics (RNAZ) Stock Up 240% Today?

TransCode Therapeutics (NASDAQ:RNAZ) shares took off after it announced positive results from a study of its lead drug candidate TTX-MC138 in mice models bearing human glioblastoma multiforme (GBM) tumors.  Shares of the Boston-based RNA oncology company added 30.8.1% to US$2.71 in early trade on Monday.

TransCode Therapeutics stock skyrockets on positive brain cancer trial results

BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in murine models bearing human glioblastoma multiforme (GBM) tumors.

TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138

BOSTON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the dosing of the first subject in its First-in-Human Phase 0 clinical trial. The Phase 0 trial is an open-label, single-center, microdose study intended to demonstrate delivery of the radio-labeled version of TransCode's lead therapeutic candidate, TTX-MC138, to radiographically-confirmed metastases in subjects with advanced solid tumors.

TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the second quarter ended June 30, 2023, and recent business progress.

TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update

BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in non-human primates (NHPs), showing that the therapeutic effectively engaged its target and showed favorable pharmacokinetics and tissue distribution. In the study, non-human primates (n = 4) were injected with a microdose of radiolabeled TTX-MC138 and imaged by positron emission tomography-magnetic resonance imaging (PET-MRI) to determine the pharmacokinetics and tissue distribution of the therapeutic.

TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138

Stonegate Healthcare's research approach centers on conducting a thorough comparative analysis to identify potentially revolutionary assets and technologies. Dallas, Texas--(Newsfile Corp. - July 13, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in RNA Therapeutics.

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi

TransCode Therapeutics Inc. (RNAZ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

BOSTON, July 05, 2023 (GLOBE NEWSWIRE) -- Dear TransCode Therapeutics Shareholders, I want to express the optimism that permeates the management, board, and staff of TransCode as we navigate the ever-evolving oncology field and venture into the clinic with our lead candidate to treat metastatic disease. This optimism is also reflected by the fact that members of management have purchased shares of the Company in the open market in the past two weeks.

TransCode Therapeutics CEO Letter to Shareholders

BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today publication of new data relevant to its lead therapeutic candidate, TTX-MC138, in the Journal of Clinical Oncology. The abstract, published in the June 1 supplemental issue of the journal, was presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO).

TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its common stock (or common stock equivalents), together with accompanying common stock warrants, at a public offering price of $3.50 per share (or common stock equivalent) and accompanying warrants. Each share of common stock (or common stock equivalent) was sold in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $3.25 per share. The Series A-1 warrants are exercisable immediately and will expire three years from the date of issuance, and the Series A-2 warrants are exercisable immediately and will expire three years from the date of issuance. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were $7 million.

TransCode Therapeutics Announces Closing of $7 Million Public Offering

BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its public offering of an aggregate of 2,000,000 shares of its common stock (or common stock equivalents), together with accompanying common stock warrants, at a public offering price of $3.50 per share (or common stock equivalent) and accompanying warrants. Each share of common stock (or common stock equivalent) is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $3.25 per share. The Series A-1 warrants will be exercisable immediately and will expire three years from the date of issuance, and the Series A-2 warrants will be exercisable immediately and will expire three years from the date of issuance. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be $7 million.

TransCode Therapeutics Announces Pricing of $7 Million Public Offering

Study provides support for further evaluation of TransCode's lead therapeutic candidate, TTX-MC138, in clinical trials Study provides support for further evaluation of TransCode's lead therapeutic candidate, TTX-MC138, in clinical trials

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma

BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors approved a 1-for-20 reverse stock split, to be effective 4:05 p.m. Eastern Time today, May 22, 2023. TransCode common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Tuesday, May 23, 2023, under the current trading symbol, “RNAZ.” The reverse stock split was approved by TransCode's stockholders on May 10, 2023, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

TransCode Therapeutics Announces 1-for-20 Reverse Stock Split

BOSTON, April 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat cancer, announced today that it has received written approval from the Dana Farber Cancer Institute Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 0 clinical trial. The planned clinical trial is to evaluate delivery of TransCode's lead therapeutic candidate, TTX-MC138, to metastatic lesions in up to 12 cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode believes that TTX-MC138 could become a treatment for many of these cancers.

TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial

Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.” Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.”

TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a Common Stock Purchase Agreement (the “Agreement”) with White Lion Capital, LLC (“White Lion Capital”) an investor in the glioblastomas / oncology sector. The Agreement provides the Company with the right to sell White Lion Capital up to approximately $1.08 million of its common stock until May 31, 2023, subject to certain limitations and conditions. The Company intends to use the net proceeds from the transaction for working capital and general corporate purposes.

TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas

BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it will present new results and a clinical study overview at the Phase I and First-in-Human Clinical Trials in Progress Session at the 2023 American Association of Cancer Research (AACR) Annual Meeting to be held April 14-19. Studies to be highlighted as part of the Meeting's Poster Sessions include:

TransCode Therapeutics to present at AACR Annual Meeting 2023

BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded the third year of a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support the clinical evaluation of TTX-MC138, TransCode's lead therapeutic candidate for the treatment of advanced solid tumors. The award totals nearly $871,000.

TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138

BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology CompanyTM committed to more effectively treating cancer using RNA therapeutics, today announced that its previously announced sale of Series A Convertible Preferred Stock for an aggregate purchase price of $500,000 will not be consummated after the proposed purchaser advised the Company that it was not prepared to complete the transaction on the terms set forth in the Stock Purchase Agreement signed by the investor.   Accordingly, no shares of Series A Convertible Preferred Stock will be issued and sold with respect to this previously announced transaction.  The Company has reserved its legal rights with respect to this matter.

TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock

BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement with Triton Funds, LP for the sale of 60 shares of the Company's Series A Convertible Preferred Stock (“Series A Preferred Stock”), each with a stated value of $10,000 per share (the “Stated Value”), for an aggregate purchase price of $500,000 in a registered direct offering.

News for TransCode Therapeutics Stock (RNAZ)